A Warm WELCOME!
Welcome to the ITI LAMP LIGHT Blog for the Immunomix investor communities. Here you will find a focus on progress being made at ITI – and elsewhere – using LAMP in clinical and biomedical research for humans and animals. As we make progress towards commercialization, you’ll be able to follow from the investor’s perspective.
Learn more About Lamp.
Learn more About LAMP-vax Clinical Trials.
Learn more about ITI management.
Learn more about ITI
Learn more about Allergies
Learn more about Japanese Red Cedar Allergy
Learn more about Peanut Allergy
Immunomic Therapeutics Receives Chimeric LAMP Vaccines US Notice of Patent Allowance, Key to LAMP-Vax™ Vaccines
Lancaster, PA, & Rockville, MD August 2nd, 2012 – Immunomic Therapeutics, Inc., (“ITI,” Lancaster, PA) a privately-held biotechnology company with laboratories in Rockville, MD, announced that the U.S. Patent and Trademark Office is providing a Notice of Allowance for ITI’s “Chimeric Vaccines” patent in the US. This protection specifically covers vectors utilizing the company’s proprietary Lysosomal Associated Membrane Protein (LAMP) LAMP DNA vaccine platform, the core design and technology utilized in ITI’s improved LAMP-based DNA vaccine vectors being applied in the company’s R&D pipeline and clinical studies. This allowance rounds out ITI’s worldwide chimeric patent portfolio including allowances in Europe, Japan and Australia.
ITI’s VP of R&D, Dr. Teri Heiland, explained, “The invention covered under this patent represents a unique innovation in DNA vaccines. Specifically, our improved LAMP vector allows us to generate an enhanced immunological response in comparison to other DNA vaccine technologies. This Notice of Allowance represents a great day for the LAMP vaccine platform technology and ensures protection of our LAMP technology until 2022.”
CEO, Bill Hearl, Ph.D., offered, “this US patent allowance is part of an integrated strategy to commercialize a growing pipeline of leading DNA vaccine platform Intellectual Property currently fueling ITI’s emerging LAMP DNA vaccine businesses.”
The Chimeric Vaccines invention provides for chimeras of proteins and nucleic acids to generate vaccines against selected antigens. The chimeras encode antigenic sequences and domains for trafficking to an endosomal compartment, directing the antigenic protein to the MHC-II compartment in the cell, promoting enhanced immune response.
LAMP technology has demonstrated highly promising results at the research level and is being aggressively commercialized by ITI under exclusive worldwide license from Johns Hopkins University and its original inventor, Distinguished JHU Professor Dr. J. Thomas August, M.D.
Immunomic Therapeutics is currently implementing LAMP in the clinic with an investigational allergy vaccine for the treatment of rhinocinjunctivitis to Japanese Red Cedar. ITI will begin an open label, Phase I, clinical study designed to establish the safety of the LAMP-vax platform. The primary objective of this Phase I Study is to evaluate both the safety and immunological response of therapeutic doses and the dosing regimen of JRC-LAMP-Vax™ vaccine as it applies to allergy patients. The study, to be conducted in allergy clinical centers based in Atlanta, Baltimore and/or Los Angeles is expected to be begin in the Summer of 2012.